The Pharmacy Times® Brain Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to neural development, plasticity, functioning, and recovery associated with aging.
October 18th 2024
Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.
FDA Approves Vorasidenib for Adults, Pediatric Patients With Grade 2 Astrocytoma, Oligodendroglioma
August 7th 2024This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.
Read More